Cure Mapt Ftd
Public records show a registered, tax-exempt organization in good standing.
What it says it does
Cure MAPT FTD increases awareness of the brain disease commonly known as frontotemporal dementia (FTD), of the importance of genetic testing, and specifically of the disease caused by a mutation of the MAPT (microtubule-associated protein tau) gene. Through regular meetings with our volunteer Scientific Advisory Board and active members, we ensure open communication, strong advocacy, and unwavering support for the MAPT community in an effort to find a cure. We actively participate in medical and scientific conferences that are focused on the genetics of FTD and dementia-related issues. Cure MAPT FTD advocates for MAPT-specific trials and access to other FTD gene-specific trials. Currently there are no interventional, drug or gene therapy trials that are available for MAPT patients, regardless of symptom status. We actively participate in key scientific conferences worldwide, building vital connections with researchers and fostering collaboration.
- Income
- $44,297
- Spending
- $30,751
- Spent on programs
- 73%
- Reserves
- 6.2 months of spending
- Largest source of income
- donations and private grants, 100%
- Employees
- 0
- Volunteers
- 47
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
We do not score finances when yearly spending is very small or the return has too little detail. The ratios stop meaning much at that size.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Good: 81 out of 100. Higher than 70% of charities in its peer group (medical research, under $250k).
Independent board
25 of 255 of 5 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
0 of 8Reports no written whistleblower policy.
Record keeping policy
0 of 7Reports no written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (3)
- $12,846 spent. We significantly increased awareness of the brain disease commonly known as frontotemporal dementia ("FTD"), created by a mutation of the MAPT (or Microtubule-Associated Protein Tau) by actively participating, speaking at and/or sponsoring conferences that are focused on dementia. The conferences included the Alzheimer's Drug Discovery Foundation's first annual Scientific Summit, Palm Beach, FL, the Tau Global 2025 Conference in London, England, the AFTD Education Conference, in Denver, Colorado, and the Alzheimer's Association International Conference (AAIC) in Toronto, CA.
- $9,720 spent. We participated in a FDA Patient Listening Session in May 2025 which gave MAPT FTD persons and caregivers a direct platform to share their lived experiences with federal regulators and the research community. We advocated at the session, as well as at conferences, and throughout the year with the global scientific and pharma community, for MAPT-specific trials and access to other FTD gene-and tau-specific trials. To accelerate this progress, we've launched a global survey and HIPPA compliant database of individuals with MAPT mutations, making it easier for scientists to identify potential participants for clinical trials.
- As part of our mission, we provided both personal and organizational support to FTD patients and their families. This included support-group meetings, educational materials, genetic testing information, conference reimbursement, and opportunities to interface with the broader scientific community.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2025.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Worth knowing.
Recognized by the IRS in January 2026. It is too new to have a track record.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.